2023 IHN/MWPC Annual Meeting
Subject matter experts that have direct experience implementing the following ideal practices are presenting:
- Biosimilar contracting and identification of savings
- DSCSA Preparedness
- How to maximize reimbursement for hospitals/health systems
- Optimizing the 340B Drug Discount Program in an Evolving Regulatory Landscape
- Specialty pharmacy considerations, new pipeline approvals and site of care considerations in the ambulatory care landscape
Faculty will present information with a focus on how the attendee can use the information to implement it in their setting, including key takeaway points with each presentation. The audience will be engaged in polling and can ask questions to further their knowledge and confidence.
Target Audience
- Pharmacists
- Other Healthcare Professionals
Learning Objectives
08/30/2023 – The Final Countdown… to DSCSA – 1.0 Contact Hours |
Carolyn Liptak, MBA, BSPharm Pharmacy Executive Director Vizient |
At the conclusion of this activity, pharmacists should be able to: |
|
08/31/202 - Against the wind… STOP running against the wind of biosimilars – 0.5 Contact Hours |
Shannon Smallwood, PharmD, BCPS Pharmacy Executive Vizient
|
At the conclusion of this activity, pharmacists should be able to: |
|
08/31/202 - Take it to the Limit... Maximizing Reimbursement Payment Limits– 0.5 Contact Hours |
Carolyn Liptak, MBA, BSPharm Pharmacy Executive Director Vizient |
At the conclusion of this activity, pharmacists should be able to: |
|
08/31/2023 - Under Pressure…The Site of Care Challenge Causing More Pressure – 0.75 Contact Hours |
Carina Dolan, PharmD, MSPharm, BCOP AVP Vizient |
At the conclusion of this activity, pharmacists should be able to: |
|
08/31/2023 - Upside down you’re turning me…let’s talk about 340B – 1.0 Contact Hours |
Greg Medley, PharmD, MBA, 340B ACE, FASCP Senior Director Vizient |
At the conclusion of this activity, pharmacists should be able to: |
|
Additional Information
Attachment | Size |
---|---|
![]() | 134.66 KB |
Faculty
Planning Committee
Alex Parish, PharmD, MBA
Pharmacy Executive
Vizient
Michelle Smith, PharmD, BCPS
Pharmacy Executive
Vizient
Shannon Smallwood, PharmD, BCPS
Pharmacy Executive
Vizient
Carolyn Liptak, MBA, BSPharm
Pharmacy Executive Director
Vizient
Carina Dolan, PharmD, MSPharm, BCOP
AVP
Vizient
Greg Medley, PharmD, MBA, 340B ACE, FASCP
Senior Director
Vizient
Faculty
Shannon Smallwood, PharmD, BCPS
Pharmacy Executive
Vizient
Carolyn Liptak, MBA, BSPharm
Pharmacy Executive Director
Vizient
Carina Dolan, PharmD, MSPharm, BCOP
AVP
Vizient
Greg Medley, PharmD, MBA, 340B ACE, FASCP
Senior Director
Vizient
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.”
Evidence-based Content: “Low/absence of evidence-based topics are mentioned within this activity”
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
![](https://continuingeducation.vizientinc.com/sites/default/files/styles/media_thumbnail/public/media/2022-06/Jointly_Accredited_Provider_JPEG.jpg?itok=lXHaI2tR)
Pharmacy
Vizient, Inc. designates this live activity for a maximum of 3.75 ACPE credit hours.
UAN JA0006103-0000-23-078-L04-P
Other Healthcare Professionals (General CE Credit)
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 3.75 ACPE Pharmacist
- 3.75 General CE - Attendance